Trinity Life Sciences Assesses Pharma/Biotech Commercial Performance Trends

Home / Media Center / News / Trinity Life Sciences Assesses Pharma/Biotech Commercial Performance Trends

Waltham, Mass., May 6, 2020 — Trinity Life Sciences, a leader in global life sciences commercialization solutions, announced the availability of its 2019 Trinity Drug Index, a commercial analysis of 26 unique therapeutic agents approved in 2016. The Index shows several new trends in drug approvals and evaluates actual commercial performance of novel drugs post-approval.

The Trinity Drug Index outlines key themes and emerging trends in the industry as more targeted and innovative products emerge. Scoring is based on a combination of clinical/therapeutic, commercial, and R&D factors.

In one key finding, the commercial performance of products approved in 2016 was more closely correlated to their clinical/therapeutic value than in previous years. Dave Fitzhenry, Trinity CEO, said, “This is an important finding, implying the launched drugs’ therapeutic value translated more directly into commercial performance than in the past.”

Although the number of new therapeutic agents decreased from the 50+ new entities in each of the previous two years, half of the 26 featured in the 2019 report are biologic products, including novel nucleic acid and cell-based therapies. Neurology products outpaced oncology in terms of percent of total approvals, representing two of the five highest scoring products in this year’s cohort, both for rare early onset neurologic indications. Metabolics accounted for 15% of approvals, while oncology showed a relative decrease from the previous year, from 30% to 15%. Infectious disease products saw an uptick. The list also featured significantly more “first-launch” companies compared to recent years. Four of them–Intercept, Sarepta, Acadia, and Clovis–are profiled in the report.

Looking ahead to the 2020 Trinity Drug Index, which will track the performance of novel drugs approved in 2017, analysts report that approvals are back up, totaling 46 products. They cover a wide range of disease areas, including 18 for orphan diseases and 15 first-in-class therapeutics.

For a copy of the report, you are invited to visit: The 2019 Trinity Drug Index.

About Trinity Life Sciences

Trinity Life Sciences is a trusted strategic partner, providing evidence-based solutions for the life sciences. With over 20 years of experience, Trinity is committed to solving clients’ most challenging problems through exceptional levels of service, powerful tools, and data-driven insights. Trinity’s range of products and solutions includes industry-leading benchmarking solutions, powered by TGaS Advisors. To learn more about how Trinity is elevating life sciences and driving evidence to action, visit

For more information:                 
Elizabeth Marshall                  
Trinity Life Sciences                   

Sign up for the latest intelligence

By signing up, you are agreeing to our Privacy Policy.

By submitting this form, creating an account, and/or using our website (or using our Services) you agree to our Privacy Policy. Information provided by you is stored in our database and may be used for sending you additional information about Trinity (including Trinity’s partners and affiliates) and our products and services. Such information may be transferred for this purpose to Trinity and affiliates in other countries. If you would like to opt out in the future, please email